Pfizer’s anti-emetic Cerenia has gained licences for use in puppies from as young as eight weeks of age, and in cats from 16 weeks of age, in the prevention and treatment of vomiting and reduction of nausea.
The only anti-emetic to use maropitant citrate, Cerenia, has gained licences for use in puppies from as young as eight weeks of age and now in cats from 16 weeks of age in the prevention and treatment of vomiting and reduction of nausea.
The licence for Cerenia’s use with cats in the injectable form provides a feline solution for the veterinary profession where the brand is already widely used and trusted in the prevention and treatment of vomiting in dogs.
The NK-1 receptor antagonist (effective against both peripheral and central emetic stimuli by acting on the final common pathway for emesis) is the only NK-1 receptor antagonist licensed for dogs and cats.
In addition to the use for general emesis in puppies, Cerenia can also be used for chemotherapy-induced nausea in dogs.
Cerenia product manager Kate Grocott said of the new licences: “Being able to deploy Cerenia in these cases, will improve quality of life, and increases the likelihood of the animal voluntarily taking food and water thereby assisting in the recovery where there is underlying disease.”
The new licence for treatment of cats with Cerenia is associated with the injectable form, while puppies may be treated with either an injection or tablets.
- For further information, contact your Pfizer Animal Health account manager or call 0845 300 8034.